TRAW — Traws Pharma, Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 1130598 ·
Last close
$0.84
Market Cap
$12.69M
52W High
$3.23
52W Low
$0.64
ADV30
1,654,001
Next earnings
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., Knight Therapeutics Inc., Specialised Therapeutics Asia Pte. Ltd., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -6,946,000 -7,107,000 8,156,000 3,133,000 13,467,000
Dec 2025 0 -7,368,000 -7,443,000 10,617,000 3,820,000 11,246,000
Sep 2025 0 -4,055,000 -3,962,000 12,443,000 6,420,000 7,898,000
Jun 2025 2,733,000 -1,249,000 -915,000 15,622,000 13,081,000 7,360,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-15,324,000
Investing CF
$-2,585,000
Financing CF
$5,088,000
CapEx
Dividends Paid
Buybacks
EPS Diluted TTM
$1.11
As of
2026-06-07

Balance + Analyst (yfinance extras)

Retained Earnings
$-647,091,000
Inventory
Receivables
$1,687,000
ST Investments
EBIT TTM
$-19,618,000
Pretax Income TTM
$-19,427,000
Interest Exp TTM
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,733,000
EBITDA
$-19,514,000
Free Cash Flow
$-10,347,250
Enterprise Value
$9,555,685
Total Cash
$3,133,000
Total Debt
$0
Shares Out
15,150,669
Trailing EPS
$-1.87
Book Value
$-0.07
ROE
-5639.2%
ROA
-90.1%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 2,790,000 -17,875,000 9,170,000 10,617,000 11,246,000 -18,185,000
Dec 2024 226,000 -24,910,000 -166,523,000 24,962,000 56,592,000 -29,792,000
Dec 2023 226,000 -20,298,000 -18,948,000 22,683,000 12,011,000 -17,932,000
Dec 2022 226,000 -19,627,000 -18,964,000 39,372,000 11,063,000 -16,294,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-1.98

Peers — same industry

TickerNameMarket CapLastDaily %
CALC CalciMedica, Inc. $12.69M $0.80
BFRG BullFrog AI Holdings, Inc. $12.28M $0.66
BFRI Biofrontera Inc. $13.19M $1.03
PHIO Phio Pharmaceuticals Corp. $12.08M $1.04
APUS Apimeds Pharmaceuticals US, Inc. $13.43M $0.89

News headlines (Yahoo Finance, 1h cache)

Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program
2026-06-22 11:00 · Yahoo
SpaceX initiated, Salesforce upgraded: Wall Street's top analyst calls
2026-06-18 13:35 · Yahoo
Traws Pharma Shares Slide After UK Regulator Postpones Influenza Study
2026-06-15 10:26 · Yahoo
Why Did TRAW Stock Slump 28% After Hours?
2026-06-13 00:07 · Yahoo
Traws Pharma Provides Regulatory Update on Influenza Program
2026-06-12 21:30 · Yahoo
Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks
2026-05-27 12:45 · Yahoo
Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results
2026-05-15 11:00 · Yahoo
Sector Update: Healthcare Stocks Lower Late Afternoon
2026-05-08 19:58 · Yahoo
Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections
2026-05-08 11:30 · Yahoo
Traws Pharma, Inc. (TRAW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
2026-04-20 13:55 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.